Shots:
- The P-IIb clinical trial involves evaluating the efficacy and safety of eliapixant (25/75/150mg, PO, bid) vs PBO in 300 patients with refractory chronic cough for 12wks.
- The trial met its 1EPs that showed an improvement in 24hrs. cough counts @12wks. of treatment. The results showed a favorable safety and tolerability profile of the therapy
- Eliapixant is a potent and selective P2X3 receptor antagonist. The therapy is currently being evaluated in P-II clinical trials for the treatment of endometriosis, overactive bladder, and neuropathic pain
Click here to to read full press release/ article | Ref: Bayer | Image: Business Standard
The post Bayer Reports Results of Eliapixant (BAY1817080) in P-IIb Study for the Treatment of Refractory Chronic Cough first appeared on PharmaShots.
